Research Analysts Offer Predictions for Landos Biopharma, Inc.’s Q1 2021 Earnings (NASDAQ:LABP)
Landos Biopharma, Inc. (NASDAQ:LABP) – Investment analysts at Jefferies Financial Group lifted their Q1 2021 earnings per share estimates for shares of Landos Biopharma in a research report issued on Monday, April 5th. Jefferies Financial Group analyst C. Howerton now forecasts that the company will post earnings per share of ($0.45) for the quarter, up from their previous forecast of ($0.46). Jefferies Financial Group currently has a “Buy” rating and a $32.00 target price on the stock. Jefferies Financial Group also issued estimates for Landos Biopharma’s Q2 2021 earnings at ($0.47) EPS, Q3 2021 earnings at ($0.47) EPS, Q4 2021 earnings at ($0.47) EPS, FY2021 earnings at ($1.87) EPS, FY2022 earnings at ($4.41) EPS, FY2023 earnings at ($6.13) EPS, FY2024 earnings at ($5.09) EPS and FY2025 earnings at ($2.99) EPS.
A number of other equities analysts have also commented on LABP. Raymond James reiterated an “outperform” rating and issued a $33.00 price objective on shares of Landos Biopharma in a report on Monday, March 8th. SVB Leerink assumed coverage on Landos Biopharma in a research note on Monday, March 8th. They issued an “outperform” rating and a $20.00 price target on the stock. Finally, JPMorgan Chase & Co. assumed coverage on Landos Biopharma in a research note on Monday, March 8th. They set a “neutral” rating and a $17.00 price objective for the company.
In other news, Director Konstantin Poukalov bought 27,453 shares of the firm’s stock in a transaction dated Friday, February 5th. The stock was bought at an average price of $11.14 per share, for a total transaction of $305,826.42. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Perceptive Advisors Llc purchased 1,250,000 shares of the stock in a transaction dated Monday, February 8th. The stock was purchased at an average price of $16.00 per share, with a total value of $20,000,000.00. The disclosure for this purchase can be found here. Over the last three months, insiders have acquired 1,902,453 shares of company stock valued at $30,305,826.
About Landos Biopharma
Landos Biopharma, Inc, a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate in development is BT-11, an oral lanthionine synthetase C-like protein 2 (LANCL2) agonist for the treatment of ulcerative colitis (UC), Crohn's disease (CD), and inflammatory bowel diseases.
Further Reading: Market Timing
Receive News & Ratings for Landos Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landos Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.